<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1005" relname="span">Echinochrome A</segment>
<segment id="3" parent="2" relname="restatement">( Ech A )</segment>
<segment id="4" parent="1004" relname="same_unit">is a dark red pigment</segment>
<segment id="5" parent="1004" relname="elaboration">separated from sea urchin shell and spine</segment>
<segment id="6" parent="1002" relname="joint">and has a chemical structure of 6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone .</segment>
<segment id="7" parent="1008" relname="span">As a main active component of a commercial therapeutic agent</segment>
<segment id="8" parent="7" relname="elaboration">called ‘ histochrome ’ ,</segment>
<segment id="9" parent="1007" relname="same_unit">Ech A has been used for the treatment of cardiovascular disorders and ophthalmopathic complications in Russia .</segment>
<segment id="10" parent="1006" relname="joint">Among the several biological benefits of Ech A , anti-oxidant and anti-inflammatory capacity is proposed as a major underlying therapeutic mechanism .</segment>
<segment id="11" parent="1012" relname="span">Indeed , Ech A has been shown to attenuate the oxidative stress</segment>
<segment id="12" parent="1013" relname="span">caused by reactive oxygen species</segment>
<segment id="13" parent="12" relname="elaboration">( ROS )</segment>
<segment id="14" parent="1014" relname="span">and cardiac toxic drugs ,</segment>
<segment id="15" parent="1015" relname="span">providing mitochondrial protection of cardiomyocyte .</segment>
<segment id="16" parent="1016" relname="span">Park et al. have reported similar observations</segment>
<segment id="17" parent="18" relname="attribution">showing</segment>
<segment id="18" parent="1017" relname="span">that Ech A reduced both cellular and mitochondrial ROS levels of patient-derived cardiac progenitors during the oxidative stress situation .</segment>
<segment id="19" parent="1006" relname="joint">The anti-oxidative and anti-viral activity of Ech A</segment>
<segment id="20" parent="1020" relname="span">has also been proved in vitro</segment>
<segment id="21" parent="20" relname="means">using a tick-borne encephalitis virus and herpes simplex virus type 1-infected cell models .</segment>
<segment id="22" parent="1022" relname="span">The therapeutic potential of Ech A was also evaluated in an experimental gastric ulcer model</segment>
<segment id="23" parent="1023" relname="span">where Ech A provided anti-ulcerogenic effects</segment>
<segment id="24" parent="23" relname="means">by increasing endogenous enzymatic and non-enzymatic antioxidant levels in vivo .</segment>
<segment id="25" parent="1026" relname="span">In another study , Ech A treatment could reduce ROS production and pro-inflammatory tumor necrosis factor-α</segment>
<segment id="26" parent="25" relname="elaboration">( TNF-α )</segment>
<segment id="27" parent="1027" relname="span">secretion in a rat model of acute uveitis</segment>
<segment id="28" parent="27" relname="elaboration">induced by lipopolysaccharide injection .</segment>
<segment id="29" parent="30" relname="attribution">These previous findings imply</segment>
<segment id="30" parent="1030" relname="span">that Ech A could exert a wide range of therapeutic impacts on other oxidative stress-related and inflammatory pathologic conditions ;</segment>
<segment id="31" parent="1031" relname="span">however , the cell-type specific regulation of Ech A on the immune system ,</segment>
<segment id="32" parent="1032" relname="same_unit">which consists of various innate and adaptive immune cells ,</segment>
<segment id="33" parent="1032" relname="same_unit">has not been elucidated yet .</segment>
<segment id="34" parent="1036" relname="span">Inflammatory bowel disease</segment>
<segment id="35" parent="34" relname="elaboration">( IBD )</segment>
<segment id="36" parent="1035" relname="same_unit">is an intractable , chronic inflammatory disease of the digestive tract</segment>
<segment id="37" parent="1038" relname="span">and Crohn &apos;s disease</segment>
<segment id="38" parent="37" relname="restatement">( CD )</segment>
<segment id="39" parent="1040" relname="span">and ulcerative colitis</segment>
<segment id="40" parent="39" relname="elaboration">( UC )</segment>
<segment id="41" parent="1039" relname="same_unit">are the major types of IBD .</segment>
<segment id="42" parent="1041" relname="joint">The etiology and pathogenic mechanisms of IBD remain largely unknown</segment>
<segment id="43" parent="1043" relname="preparation">and both environmental factors and genetic factors combined with immunological dysfunction seem to drive IBD development .</segment>
<segment id="44" parent="1044" relname="preparation">To attenuate the excessive immune response ,</segment>
<segment id="45" parent="1045" relname="preparation">advanced immunotherapy</segment>
<segment id="46" parent="1046" relname="preparation">using immune-modulators such as inflammatory cytokine blockers has been used recently ;</segment>
<segment id="47" parent="1047" relname="span">however , the presence of non-responder and uncontrolled side effects are the common challenging issues</segment>
<segment id="48" parent="47" relname="circumstance">when using immunotherapy .</segment>
<segment id="49" parent="1049" relname="span">Therefore , there has been an unmet need</segment>
<segment id="50" parent="49" relname="purpose">to develop novel therapeutics for the effective management of IBD .</segment>
<segment id="51" parent="1052" relname="attribution">In this study , we investigated</segment>
<segment id="52" parent="1052" relname="span">whether Ech A could exhibit a protective role in IBD progression</segment>
<segment id="53" parent="1053" relname="span">using a chemical colitogen dextran sodium sulfate</segment>
<segment id="54" parent="53" relname="elaboration">( DSS)-induced colitis mice model .</segment>
<segment id="55" parent="1055" relname="span">To explore the therapeutic mechanism of Ech A , we also performed in vitro proliferation and polarization experiments with two major innate and adaptive immune cells , macrophage and CD4+ helper T cells</segment>
<segment id="56" parent="55" relname="evidence">( Th cells ) , respectively .</segment>
<segment id="57" parent="1058" relname="attribution">Our in vivo findings suggest</segment>
<segment id="58" parent="1058" relname="span">that Ech A could attenuate the clinical signs , as well as histological improvement , for the first time in a colitis model</segment>
<segment id="59" parent="58" relname="elaboration">which represents IBD .</segment>
<segment id="60" parent="61" relname="attribution">More importantly , in vitro results demonstrate</segment>
<segment id="61" parent="1059" relname="span">that the anti-inflammatory function of Ech A is manifested by , in part , inducing immunomodulatory effector cells , such as M2 macrophages and Treg cells .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1006" relname="background"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1004" type="multinuc" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="same_unit"/>
<group id="1006" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="multinuc" parent="1006" relname="joint"/>
<group id="1008" type="span" parent="1007" relname="same_unit"/>
<group id="1011" type="multinuc" parent="1006" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="same_unit"/>
<group id="1013" type="span" parent="11" relname="elaboration"/>
<group id="1014" type="span" parent="1011" relname="same_unit"/>
<group id="1015" type="span" parent="14" relname="elaboration"/>
<group id="1016" type="span" parent="15" relname="elaboration"/>
<group id="1017" type="span" parent="16" relname="elaboration"/>
<group id="1020" type="span" parent="1006" relname="joint"/>
<group id="1021" type="span" parent="1006" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="span"/>
<group id="1023" type="span" parent="22" relname="elaboration"/>
<group id="1024" type="multinuc" parent="1022" relname="elaboration"/>
<group id="1025" type="multinuc" parent="1024" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="same_unit"/>
<group id="1027" type="span" parent="1025" relname="same_unit"/>
<group id="1028" type="multinuc" parent="1024" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1031" type="span" parent="1029" relname="same_unit"/>
<group id="1032" type="multinuc" parent="31" relname="elaboration"/>
<group id="1033" type="multinuc" parent="1028" relname="joint"/>
<group id="1034" type="multinuc" parent="1033" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="same_unit"/>
<group id="1037" type="multinuc" parent="1034" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="same_unit"/>
<group id="1039" type="multinuc" parent="1037" relname="same_unit"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1041" type="multinuc" parent="1033" relname="joint"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1044" relname="span"/>
<group id="1046" type="multinuc" parent="1045" relname="span"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1048" type="multinuc" parent="1046" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="1048" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="span" parent="1051" relname="span"/>
<group id="1053" type="span" parent="52" relname="means"/>
<group id="1054" type="multinuc" parent="1051" relname="purpose"/>
<group id="1055" type="span" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1054" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="joint"/>
<group id="1058" type="span" parent="1057" relname="span"/>
<group id="1059" type="span" parent="1056" relname="joint"/>
	</body>
</rst>
